For more information on becoming an event/media partner, please contact Jon Liong at email@example.com.
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.
ZHANGJIANG LIFE SCIENCE CLUSTER
In 1996, Zhangjiang biotech & pharmaceutical industrial base (Zhangjiang Life Science Cluster) was founded by the Ministry of Science and Technology, the Ministry of Health, Food and Drug Administration, the Chinese Academy of Sciences and the Shanghai Municipal People's Government. With more than 20 years development, the Innopark has achieved the fundamental transformation from global agglomeration led to innovation led high tech base. Zhangjiang has established the innovation cluster of biotechnology and pharmaceutical industries, and has become an exemplary high-tech zone with enormous concentration of R&D resources, fast emergence of innovative outcomes, and numerous breakthroughs brought by recent technologies and models.
Over the past 20 years, Zhangjiang has focused on creating an innovative Eco-system including over 600 biotech and pharmaceutical companies. There are more than 30 global leading research platforms and major scientific research facilities, more than 30 R&D centers and research universities of profound achievements, more than 30 multinational pharmaceutical R&D headquarters, more than 450 small and medium-sized start-ups and more than 40 domestic and foreign drug development service outsourcing enterprises chose Zhangjiang as their base. About 40 thousand biopharmaceutical talents are gathering here. At the same time, Zhangjiang has also established the complete industrial system covering research, development and CMO facility under MAH policy.
In 2017, Zhangjiang biotech and pharmaceutical start-ups have got investment of over 2.6 Billion(RMB) totally in Zhangjiang. Every three new drugs approved by the Food and Drug Administration, one is from Zhangjiang Life Science Cluster; one third of fund from "The Major Project of Important New Drug Discovery" is applied by companies in Zhangjiang Life Science Cluster; the clinical trial approval rate of new drugs of enterprises from Zhangjiang Life Science Cluster is three times of the national average level.
Biodiscover (www.biodiscover.com) is a newly media portal to explore the value of biosciences, and committed to disseminate the forefront of biotechnology and successful business model in the field of life sciences. Biodiscover.com has more than 13,000 registered users so far. Additionally, our website gains over 2000,000 page views per month.
Our website introduces the most advanced and dynamic bioinformatics technology in the field of life sciences, providing prospective, in-depth research information and technical topics for biologists in china; providing the latest bioindustry dynamics and reports for enterprises; providing a interaction platform for biological enterprises and individuals; integrating the latest exhibitions, conferences and technical seminars of biopharmaceutical etc.
Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of initiatives accelerating the globalization of China's life science industry. ChinaBio has helped China companies raise nearly $400 million and global life science companies identify over 400 licensing and acquisition opportunities in China.
- Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees.
- Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy.
- Transactions: ChinaBio Capital helps companies secure partnerships and acquisitions and access private and government funding in China.
- Publishing: ChinaBio Today is the most widely read online and email newsletter on China's life science industry.
Founded in Shanghai in 2002, GBI has built a diverse portfolio of market intelligence solutions for pharmaceutical and device companies and other service providers. Focused on China and the Latin American markets, GBI’s value-added industry information, news, and data services power individuals and organizations’ decision-making and enable more effective communication. As a trusted source of information, GBI has established long-term relationships with both multinational players and local firms, and continues to drive forward the health care industry.
GBI has offices in Shanghai, Beijing, and Washington D.C.
Healthcare Drinks China
Healthcare Drinks (HCD) is a platform with a popular series of after work networking events for the medical industry organized by leading healthcare executives. It was started in Shanghai and there are active chapters in Beijing, Boston, Changsha, Guangzhou, Hong Kong, Kunming, Melbourne, Singapore, San Francisco, Shenzhen and Taipei. (www.healthcaredrinks.com)
Insight Pharma Data
【医疗器械】 器械注册查询 全面掌握行业动态
Mergermarket is an independent Mergers and Acquisitions (M&A) intelligence service with an unrivalled network of dedicated M&A journalists based in 67 locations across the Americas, Europe, Asia- Pacific, the Middle-East, and Africa. Unlike any other service of its kind, Mergermarket specialises in providing forward-looking origination and deal flow opportunities integrated with a comprehensive deals database – resulting in real revenues for clients.
Founded by industry-recognized editors, RNDer and PharmaDJ are the leading publications providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers.